VERTEX PRESENTS DATA FOR HCV STUDY

A A

Clinical data presented at the annual meeting of the American Association for the Study of Liver Diseases, being held in San Francisco, confirm that VX-950, an investigational oral hepatitis C protease inhibitor developed by Vertex Pharmaceuticals, was well-tolerated and possessed potent antiviral activity in a 14-day study in patients with hepatitis C virus (HCV) infection.

The rapid decline in plasma HCV-RNA levels observed in HCV patients taking VX-950, together with a viral kinetic analysis that projects the potential duration of treatment required to achieve sustained virologic response, support the evaluation of VX-950 in a novel, three-month combination treatment paradigm. Vertex has filed an investigational new drug application with the FDA to support Phase II clinical development of VX-950.